[Minimum negative lymph node dissection during radical gastrectomy for gastric cancer: a 22-year, single-center retrospective study].

J Chen(Fudan University Shanghai Cancer Center), F L Liu(Fudan University Shanghai Cancer Center), Haimin Pan(Fudan University Shanghai Cancer Center), Jie Lu(The People's Hospital of Guangxi Zhuang Autonomous Region), Bin Ke(Tianjin Medical University Cancer Institute and Hospital), Yunpeng Liu(Shenyang Institute of Automation), Mingde Zang(Fudan University Shanghai Cancer Center), K.S. Hu(Fudan University Shanghai Cancer Center), Zheng‐Wen Long(Shanxi Normal University)
PubMed
September 25, 2025
10.3760/cma.j.cn441530-20250603-00210
Cited by 0

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412